Canada markets closed
  • S&P/TSX

    17,906.02
    +60.11 (+0.34%)
     
  • S&P 500

    3,855.36
    +13.89 (+0.36%)
     
  • DOW

    30,960.00
    -36.98 (-0.12%)
     
  • CAD/USD

    0.7849
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    52.87
    +0.10 (+0.19%)
     
  • BTC-CAD

    41,373.11
    -1,194.59 (-2.81%)
     
  • CMC Crypto 200

    653.79
    -23.11 (-3.41%)
     
  • GOLD FUTURES

    1,854.40
    -0.80 (-0.04%)
     
  • RUSSELL 2000

    2,163.27
    -5.49 (-0.25%)
     
  • 10-Yr Bond

    1.0400
    -0.0510 (-4.67%)
     
  • NASDAQ futures

    13,467.00
    -8.50 (-0.06%)
     
  • VOLATILITY

    23.19
    +1.28 (+5.84%)
     
  • FTSE

    6,638.85
    -56.22 (-0.84%)
     
  • NIKKEI 225

    28,822.29
    +190.84 (+0.67%)
     
  • CAD/EUR

    0.6461
    +0.0011 (+0.17%)
     

COVAXX to Participate in Opening Keynote Panel with FDA and WHO experts on SARS-CoV-2 at the World Vaccine & Immunotherapy Conference West Coast December 1, 2020

Newsfile Corp.
·1 min read

Hauppauge, New York--(Newsfile Corp. - November 30, 2020) - COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced that Chief Scientific Officer, Farshad Guirakhoo, Ph.D. will participate in the Opening Keynote panel discussion, "SARS-CoV-2 - We have a vaccine-what now?" at the virtual World Vaccine & Immunotherapy Conference West Coast on Tuesday, December 1, at 12:00 pm PST.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • COVAXX's CSO, Farshad Guirakhoo, Ph.D., to participate in keynote panel about COVID vaccines on Dec. 1, 2020

Click image above to view full announcement.

Contacts:

Ignacio Guerrero-Ros, Ph.D.
(646) 942-5604
Ignacio.Guerrero-Ros@russopartnersllc.com

Diane Murphy
(310) 658.8756
diane@covaxx.com

David Schull
(212) 845-4271
David.Schull@russopartnersllc.com

Source: COVAXX

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69178